News & Events:JNJ

JOHNSON & JOHNSON - * JOHNSON & JOHNSON APPOINTS THIBAUT MONGON AS CEO DESIGNATE OF PLANNED NEW CONSUMER HEALTH COMPANY. * J&J - PLANNED SEPARATION OF CONSUMER HEALTH BUSINESS EXPECTED TO OCCUR WITHIN 2023. * J&J - APPOINTED PAUL RUH AS CFO DESIGNATE OF FUTURE, LISTED NEW CONSUMER HEALTH COMPANY.

Johnson & Johnson (JNJ) on Wednesday appointed Thibaut Mongon as the chief executive officer of the consumer health division, which the pharmaceutical giant plans to spin off into a listed company by the end of next year.

The Company has also appointed Paul Ruh as CFO Designate Mongon and Ruh to Assume New Leadership Roles Upon the Completion of the Planned Separation of the Consumer Health Business Planned Separation Expected to Occur in 2023 NEW BRUNSWICK, N.J., May 11, 2022 /PRNewswire/ -- Johnson & Johnson (JNJ) today announced the appointment of Thibaut Mongon as Chief Executive Officer Designate and Paul Ruh ...

A lawyer for two Ohio counties said on Monday that CVS Health Corp (CVS), Walgreens Boots Alliance Inc (WBA) and Walmart Inc (WMT) should fund an $878 million plan to address the opioid crisis there, as a first-of-its-kind trial got underway to determine the pharmacy chains' contribution.

Here's what you need to know about the pandemic right now: Tesla stutters under tighter Shanghai lockdown; Beijing keeps hunting COVID. Tesla operated its Shanghai plant well below capacity on Tuesday, showing the problems factories face trying to ramp up output under a tightening COVID lockdown, while China's capital kept up its fight with a small but stubborn outbreak.

CVS Health Corp (CVS), Walgreens Boots Alliance Inc (WBA) and Walmart Inc (WMT) on Tuesday begin a first-of-its-kind trial to determine what the pharmacy chains owe for their role in the opioid epidemic in two Ohio counties, which are seeking $878 million.

A whale with a lot of money to spend has taken a noticeably bullish stance on Johnson & Johnson. Looking at options history for Johnson & Johnson we detected 20 strange trades. If we consider the specifics of each trade, it is accurate to state that 65% of the investors opened trades with bullish expectations and 35% with bearish.

* South Africa's Aspen facing poor demand for shots. * Could slash production without orders. * WHO, Gavi say supplies for COVAX initiative already secured. By Promit Mukherjee and Jennifer Rigby.

COVID-19 vaccine makers are shifting gears and planning for a smaller, more competitive booster shot market after delivering as many doses as fast as they could over the last 18 months.

Johnson & Johnson (JNJ): * JANSSEN DISCONTINUES COLLABORATION AND LICENSE AGREEMENTS WITH BAVARIAN NORDIC IN HEPATITIS B AND HUMAN PAPILLOMAVIRUS. * COLLABORATIONS BETWEEN JANSSEN AND BAVARIAN NORDIC IN HIV AND EBOLA CONTINUE. * NO CLINICAL STUDIES IN HEPATITIS B HAVE BEEN INITIATED BY JANSSEN UTILIZING MVA-BN TECHNOLOGY.

- The following is a summary of some recent studies on COVID-19. Obesity may weaken vaccine protection in the never infected. Severe obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.

The following is a summary of some recent studies on COVID-19. Obesity may weaken vaccine protection in the never infected. Severe obesity may weaken the effectiveness of COVID-19 vaccines in those who have never been infected with the coronavirus, according to a small Turkish study.

Here's a roundup of top developments in the biotech space over the last 24 hours. The FDA said it was limiting the use of Johnson & Johnson's  COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome.

On CNBC's "Mad Money Lightning Round," Jim Cramer said Western Midstream Partners LP has a great yield. Cramer recommended staying away from CoreCivic, Inc.. When asked about Inmode Ltd, Cramer said, "If you want medtech, you just want Edwards Lifesciences Corporation ." The "Mad Money" host said SGHC Limited is "doing well, and I don't say that idly."

Here's what you need to know about the pandemic right now: China hits back at 'zero COVID' doubters. Residents of Beijing fretted on Friday over dozens of new COVID-19 cases reported daily and over the possibility of more restrictions on movements as China's leaders threatened action against critics of their zero-COVID policy.

Reuters IHG Hotels & Resorts On Way To Recovery As Travel Booms Tesla Battery Supplier CATL Said To Actively Explore Sites For US Manufacturing Plants US Regulators Reach China For Audit Deal Discussions Tesla Will Run Two Shifts At Shanghai Plant From May 16 Wall Street Journal Facebook Deliberately Caused Chaos In Attempt To Thwart Unfavorable Australian Law, Whistleblowers Allege Closely Wat...

The FDA said it was limiting the use of Johnson & Johnson's  COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome. The J&J shot can be administered in cases where authorized or approved COVID-19 vaccines are not accessible, or if an individual is less keen on using the other two shots, the FDA said.

The following are the top stories on the New York Times business pages. - U.S. President Joe Biden, Vice President Kamala Harris and Labor Secretary Martin J. Walsh met at the White House with several union organizers involved in successful campaigns at companies including Amazon (AMZN) and Starbucks (SBUX). nyti.ms/3KN4695.

The following are the top stories in the Wall Street Journal. - Bausch + Lomb Corp priced its IPO at $18 a share, falling short of expectations as it became the first big company in months to try going public into a turbulent stock market. https://on.wsj.com/3MRJw95.

The U.S. health regulator said on Thursday it was limiting the use of Johnson & Johnson's COVID-19 vaccine for adults due to the risk of a rare blood clotting syndrome, the latest setback to the shot that has been eclipsed by rivals.